Prioritization of research addressing management strategies for ductal carcinoma in situ

Annals of Internal Medicine

Volumn 160, Issue 7, 2014, Pages 484-491

  Gierisch, Jennifer M ^a   Myers, Evan R ^a   Schmit, Kristine M ^b   Crowley, Matthew J ^c   McCrory, Douglas C ^b   Chatterjee, Ranee ^d   Coeytaux, Remy R ^b   Kendrick, Amy ^b   Sanders, Gillian D ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d Sutton Station Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CONCEPTUAL FRAMEWORK; CONFLICT OF INTEREST; CONSUMER; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MEDICAL RESEARCH; METHODOLOGY; PATIENT ADVOCACY; PRIORITY JOURNAL; RESEARCH PRIORITY; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); UNCERTAINTY;

ADULT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EVIDENCE-BASED MEDICINE; FEMALE; FORECASTING; HUMANS; PATIENT OUTCOME ASSESSMENT; RESEARCH; RESEARCH DESIGN;

EID: 84897371978     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M13-2548     Document Type: Article

References (16)

1. American Cancer Society. Cancer Facts & Figure 2013. Atlanta: American Cancer Soc; 2013. Accessed at www.cancer.org/research/ cancerfactsfigures /cancerfactsfigures/cancer-facts-figures-2013 on 5 September 2013.
2. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170-8. [PMID: 20071685].
3. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst. 2010;102:161-9. [PMID: 20071686].
4. National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer: diagnosis and treatment. NICE clinical guideline 80. London, UK: National Institute for Health and Clinical Excellence; 2009. Accessed at www.nice.org.uk/nicemedia/pdf/cg80niceguideline.pdf on 5 September 2013.
5. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2009: CD000563. [PMID: 19821272].
6. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012;10:CD007847. [PMID: 23076938].
7. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441-52. [PMID: 9469327].
8. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19:2263-71. [PMID: 11304780].
9. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, et al Swedish Breast Cancer Group. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45:536-43. [PMID: 16864166].
10. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M; UK Coordinating Committee on Cancer Research. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362: 95-102. [PMID: 12867108].
11. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627-37. [PMID: 20427430].
12. Ip S, Raman G, Concannon TW, Ratichek SJ, Yu W, Chang LKW, et al. Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Artery Stenting: Future Research Needs. Future Research Needs Paper no. 25. (Prepared by Tufts Evidence-based Practice Center under contract no. 290-2007-10055-I.) AHRQ publication no. 13-EHC016-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Accessed at www.effectivehealthcare. ahrq.gov/ehc/products/512/1413/coronary-arterystenting-future-130604.pdf on 13 January 2014.
13. Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ. Diagnosis and management of ductal carcinoma in situ (DCIS). Evid Rep Technol Assess (Full Rep). 2009:1-549. [PMID: 20629475].
14. Chang SM, Carey TS, Kato EU, Guise JM, Sanders GD. Identifying research needs for improving health care. Ann Intern Med. 2012;157:439-45. [PMID: 22847017].
15. Sanders GD, Powers B, Crowley M, Myers E, McBroom A, Musty M, et al. Future Research Needs for Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Future Research Needs Paper no. 8. (Prepared by Duke Evidence-based Practice Center under contract no. 290-2007-10066-I.) AHRQ publication no. 11-EHC006-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2010. Accessed at www.effectivehealthcare.ahrq.gov /ehc/products/239/ 573/Future08-ACEvsARB-11-2-2010.pdf on 9 September 2013.
16. National Research Council. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC: National Academies Pr; 2013. Accessed at www.nap.edu/catalog.php?record-id-18359 on 24 January 2014.